Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
25 evidence topics · 35 sources
Summary: limitations of endocrine and targeted therapies after a CDK4/6 inhibitor
The oral estrogen receptor degraders approved after progression on endocrine therapy (elacestrant, imlunestrant, and vepdegestrant) are indicated for ESR1-mutated disease, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. Without ESR1 mutations, the progression-free survival hazard ratio for elacestrant was 0.86 (95% CI 0.63 to 1.19) in 250 participants (52%) in EMERALD, and median progression-free survival in EMBER-3 was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In ESR1-mutated tumors, the ABC8 consensus describes “modest absolute clinical benefit” across the oral SERDs, with hazard ratios generally in the 0.55 to 0.62 range. In EMERALD, median progression-free survival was 2.8 versus 1.9 months in the overall population and 3.8 versus 1.9 months in the ESR1 mutation cohort. In the control arms of VERITAC-2 and EMBER-3, median progression-free survival was 2.1 months with fulvestrant among 270 participants with ESR1 mutations and 3.8 months with standard therapy among participants with ESR1 mutations, respectively. In real-world studies after a first-line CDK4/6 inhibitor, the weighted average median progression-free survival was 3.9 months with single-agent endocrine therapy and 6.1 months with chemotherapy, and in a second cohort, median second-line real-world progression-free survival with endocrine monotherapy was 5.0 months (n = 27).
Fulvestrant 500 mg is administered as two 5 mL intramuscular injections on Days 1, 15, 29, and once monthly thereafter, and injection site pain was reported in 11.6% of participants in the fulvestrant 500 mg group. Hyperglycemia was reported in 65% of participants treated with alpelisib, and increased fasting glucose occurred in 37% of participants treated with capivasertib and 85% of participants treated with inavolisib; adverse events led to discontinuation in 25.0% of participants receiving alpelisib (4.2% with placebo) and 13.0% of participants receiving capivasertib (2.3% with placebo). Overall survival was not significantly improved with capivasertib plus fulvestrant (hazard ratio 0.83 in the PIK3CA/AKT1/PTEN-altered subgroup), alpelisib plus fulvestrant in the PIK3CA-mutated cohort (39.3 versus 31.4 months), everolimus plus exemestane (31.0 versus 26.6 months), abemaciclib plus fulvestrant (32.1 versus 24.6 months), or imlunestrant in ESR1-mutated disease (34.5 versus 23.1 months, boundary for significance not reached). The ABC8 consensus does not recommend rechallenge with a second oral SERD or a second PI3K/AKT/mTOR inhibitor outside clinical trials, and states that following progression on a CDK4/6 inhibitor “the optimal sequence remains undefined”.
Summary: limitations of PARP inhibitors, antibody-drug conjugates, and chemotherapy
Olaparib and talazoparib are indicated for germline BRCA-mutated, HER2-negative disease, and approximately 5% of all breast cancer patients carry a germline deleterious BRCA1 and/or BRCA2 mutation. Neither improved overall survival significantly over chemotherapy: median overall survival was 19.3 months with olaparib and 17.1 months with chemotherapy (hazard ratio 0.90; 0.86 in hormone receptor-positive participants), and the overall survival hazard ratio with talazoparib was 0.827 in hormone receptor-positive participants. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of participants receiving trastuzumab deruxtecan in DESTINY-Breast04, and adjudicated interstitial lung disease or pneumonitis in 11.3% in DESTINY-Breast06; ocular adverse reactions occurred in 38% of participants treated with datopotamab deruxtecan in the pooled safety population; and grade 3 or higher treatment-related neutropenia occurred in 51% of participants receiving sacituzumab govitecan in TROPiCS-02. Overall survival with datopotamab deruxtecan was not significantly different from chemotherapy (hazard ratio 1.01), and the ABC8 consensus states that routine sequencing of antibody-drug conjugates in this setting “cannot currently be recommended”. In the TROPION-Breast01 control arm, single-agent chemotherapy produced a median progression-free survival of 4.9 months, with grade 3 or higher treatment-related adverse events in 44.7% of participants, and eribulin was not superior to capecitabine for overall survival (median 15.9 versus 14.5 months) or progression-free survival (4.1 versus 4.2 months).
ESR1 mutation restriction of oral endocrine therapy: elacestrant label
ESR1 mutation restriction of oral endocrine therapy: imlunestrant label
ESR1 mutation restriction of oral endocrine therapy: vepdegestrant label
No progression-free survival difference without ESR1 mutation: EMBER-3
“In exploratory analyses involving patients without ESR1 mutations, the median progression-free survival was 5.6 months in the imlunestrant group and 5.7 months in the standard-therapy group (hazard ratio for progression or death, 1.00; 95% CI, 0.79 to 1.27)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among patients with ER-positive, HER2-negative advanced breast cancer, treatment with imlunestrant led to significantly longer progression-free survival than standard therapy among those with ESR1 mutations but not in the overall population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Modest absolute benefit of oral SERDs: ABC8 consensus 2026
“Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of a PI3K/AKT/mTOR inhibitor after progression on another agent of the same class is not recommended outside clinical trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As multiple targeted agents are now available following progression on a CDK4/6i, the optimal sequence remains undefined; until prospective comparative data are available, the eligibility criteria of individual trials and the tumor biomarker profile should guide treatment selection.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Short progression-free survival with endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm
“Because of the initial drop in PFS in both arms, median PFS may not be a sufficient measure of efficacy in the overall population (2.8 months v 1.9 months) or ESR1 mutation cohort (3.8 months v 1.9 months).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a recent phase II trial, fulvestrant was associated with a median PFS of 1.9 months and a CBR of 13.7%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Short progression-free survival with fulvestrant after a CDK4/6 inhibitor: VERITAC-2 control arm
Short progression-free survival with standard endocrine therapy: EMBER-3 control arm
“Among patients with ESR1 mutations, the median progression-free survival was 5.5 months (95% confidence interval [CI], 3.9 to 7.4) in the imlunestrant group, as compared with 3.8 months (95% CI, 3.7 to 5.5) in the standard-therapy group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Intramuscular administration of fulvestrant: fulvestrant label
Pharmacologic limitations of fulvestrant: review
“Clinical challenges with fulvestrant can be related to pharmacologic limitations, including the absence of oral bioavailability,” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Pharmacologic limitations regarding the bioavailability of fulvestrant have prompted strong interest in an orally bioavailable alternative.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Oral route compared with intramuscular fulvestrant: ABC8 consensus 2026
“The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, showed encouraging PFS results in the VIKTORIA-1 trial, but with a demanding administration schedule and significant stomatitis burden requiring careful management” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Hyperglycemia with PI3K inhibition: alpelisib label
Hyperglycemia with AKT inhibition: capivasertib label
Hyperglycemia with PI3K-alpha inhibition: inavolisib label
Short real-world progression-free survival after first-line CDK4/6 inhibitor: US Flatiron cohort
“Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Short real-world progression-free survival in second and third lines: SOLTI-1801 CDK-PREDICT
“Median rwPFS-2L was 5.0 months for endocrine monotherapy (n = 27), 7.0 months for targeted therapies (n = 65), 7.4 months for capecitabine (n = 12), and 8.7 months for other chemotherapy agents (n = 21).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In rwPFS-3L, similar trends were seen (6.4 vs. 3.3 months; HR 1.74; 95% CI 0.98–3.08), with BL showing the poorest outcomes (HR 5.63; 95% CI 1.17–27.02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Endocrine monotherapy was consistently associated with the shortest rwPFS across lines, reinforcing its limited role in this setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Short real-world progression-free survival in second line: systematic review of real-world evidence
“The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“no studies reported disaggregated outcomes in the third-line setting or beyond” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival not statistically improved: EMBER-3 interim overall survival
“In patients with ESR1m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached].” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Overall survival not statistically improved: PARP inhibitor trials
Overall survival not statistically improved: datopotamab deruxtecan
Overall survival not statistically improved: eribulin versus capecitabine
Inevitable endocrine resistance and uncertain sequencing: reviews
“Endocrine resistance inevitably develops in the metastatic setting, often mediated by acquired ESR1 mutations that promote ligand-independent ER activation and reduce sensitivity to standard antiestrogens.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Their optimal integration and sequencing in practice remain uncertain, and for tumors harboring dual ESR1 and PIK3CA mutations, with multiple biomarker-guided options available, the best treatment strategies are unclear.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“With several oral SERDs emerging contemporaneously, data are needed to assess their relative efficacy, safety, and potential interchangeability.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote